Here, we hypothesize that the change of the CX3CR1+ subset in PB CD8+ T cells from baseline correlates with response to chemo-immunotherapy in patients with advanced NSCLC. The gene discussed is CX3CR1; the disease is non-small cell lung carcinoma.